| Title |
Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
|
|---|---|
| Published in |
Current Atherosclerosis Reports, March 2018
|
| DOI | 10.1007/s11883-018-0718-x |
| Pubmed ID | |
| Authors |
Angelos D. Karagiannis, Martin Liu, Peter P. Toth, Shijia Zhao, Devendra K. Agrawal, Peter Libby, Yiannis S. Chatzizisis |
| Abstract |
Clinical trials with PCSK9 inhibitors have shown a robust decrease in plasma LDL levels and a significant reduction in the incidence of cardiovascular atherosclerotic events. However, the role of PCSK9 in atherosclerosis is not well investigated and it remains unclear whether PCSK9 inhibition has direct, LDL-independent, anti-atherosclerotic effects. This review outlines the molecular pathways and targets of PCSK9 in atherosclerosis and summarizes the experimental and clinical data supporting the anti-atherosclerotic (pleiotropic) actions of PCSK9 inhibitors. PCSK9 is expressed by various cell types that are involved in atherosclerosis (e.g., endothelial cell, smooth muscle cell, and macrophage) and is detected inside human atherosclerotic plaque. Preclinical studies have shown that inhibition of PCSK9 can attenuate atherogenesis and plaque inflammation. Besides increasing plasma LDL, PCSK9 appears to promote the initiation and progression of atherosclerosis. Inhibition of PCSK9 may confer atheroprotection that extends beyond its lipid-lowering effects. |
X Demographics
The data shown below were collected from the profiles of 36 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 13 | 36% |
| Colombia | 3 | 8% |
| Venezuela, Bolivarian Republic of | 2 | 6% |
| Ecuador | 1 | 3% |
| Honduras | 1 | 3% |
| Argentina | 1 | 3% |
| United States | 1 | 3% |
| Mexico | 1 | 3% |
| United Kingdom | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 12 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 31 | 86% |
| Practitioners (doctors, other healthcare professionals) | 3 | 8% |
| Scientists | 2 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 89 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 15% |
| Researcher | 10 | 11% |
| Student > Bachelor | 9 | 10% |
| Student > Postgraduate | 6 | 7% |
| Student > Master | 6 | 7% |
| Other | 14 | 16% |
| Unknown | 31 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 21 | 24% |
| Medicine and Dentistry | 15 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 8% |
| Chemistry | 3 | 3% |
| Linguistics | 1 | 1% |
| Other | 5 | 6% |
| Unknown | 37 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2020.
All research outputs
#1,816,697
of 25,732,188 outputs
Outputs from Current Atherosclerosis Reports
#94
of 870 outputs
Outputs of similar age
#38,703
of 350,581 outputs
Outputs of similar age from Current Atherosclerosis Reports
#5
of 16 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 870 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.4. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,581 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.